1.1Review of existing molecular records
A reviewer extracts the gene, variant class, and result from each finalized report. A rules table marks the record positive when it documents both an FGFR3 mutation and an FGFR3 fusion.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A reviewer extracts the gene, variant class, and result from each finalized report. A rules table marks the record positive when it documents both an FGFR3 mutation and an FGFR3 fusion.
An allele-specific digital PCR assay partitions tumor DNA into droplets and uses separate fluorescent probes for the specified allele and the reference allele. The assay returns a positive result when the mutant signal exceeds the validated reporting threshold and the controls pass.
An antibody against human epidermal growth factor receptor 2 stains a fixed tumor section, and a chromogenic detection system reveals membrane staining. The report records staining intensity, completeness, and the percentage of tumor cells stained to assess eligibility for receptor-directed therapy.
The antibody binds nectin-4 on the surface of tumor cells, and the cells internalize the conjugate. Intracellular cleavage releases a payload that disrupts microtubules and arrests cell division.
An infused antibody binds programmed cell death protein 1 on T cells and blocks its interaction with inhibitory ligands. This reduces inhibitory signaling and supports T-cell activity against tumor cells.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary oncology workflow uses a bladder tumor biopsy from a dog with urothelial carcinoma. A targeted DNA panel detects substitutions in canine FGFR3, and a targeted RNA panel uses canine FGFR3 primers to detect expressed fusion transcripts. The treatment protocol assigns an FGFR inhibitor when both alterations are confirmed from the same biopsy.
A urine sediment pellet supplies DNA and RNA for paired FGFR3 testing. Centrifugation concentrates exfoliated urothelial cells, and separate extractions from the pellet supply a DNA sequencing assay for mutations and an RNA sequencing assay for fusion junctions. The treatment workflow releases an FGFR inhibitor order for clinical review when both assays yield positive results and pass their quality controls.
Droplet digital PCR substitutes for sequencing when the assay targets a predefined FGFR3 mutation and fusion junction. One reaction uses mutation-specific and reference probes on DNA, and a second reaction uses a junction-spanning probe on reverse-transcribed RNA from the same specimen. The assay compares positive droplet counts with established thresholds and reports the pair when both signals pass their cutoffs and the controls pass. A positive paired result routes the case for FGFR inhibitor treatment.
One tumor extraction supplies two DNA aliquots and two RNA aliquots, each prepared as an independently indexed sequencing library. The DNA libraries test for FGFR3 mutations, and the RNA libraries test for FGFR3 fusion junctions. The workflow requires the same mutation in both DNA libraries and the same fusion junction in both RNA libraries before it routes the case for FGFR inhibitor treatment. A discordant pair triggers repeat testing.
A laboratory information system sends separate structured results for the FGFR3 mutation and fusion to an electronic prescribing system. The prescribing system matches both results by patient and specimen identifier and checks that each result is final and positive. A matching pair opens an FGFR inhibitor order set for clinician review and signature.
A software pipeline receives indexed DNA and RNA sequencing reads and groups them by specimen identifier. It calls an FGFR3 mutation from DNA reads and detects an FGFR3 fusion from RNA reads that span a junction between FGFR3 and its partner. It checks each finding against assay-specific quality thresholds and sends passing pairs with their supporting read counts for review. A signed positive report routes the case for FGFR inhibitor treatment.
A fixed tumor section supplies DNA and RNA for separate sequencing libraries. Targeted DNA sequencing detects FGFR3 substitutions and short insertions or deletions, while anchored RNA amplification and sequencing identify FGFR3 fusion junctions.
Allele-specific fluorescent probes detect predefined FGFR3 mutations in DNA extracted from tumor tissue. A separate reverse transcription PCR panel uses primer pairs that flank predefined FGFR3 fusion junctions, and the report records a call for each alteration class.
After the report confirms both alteration classes, the patient receives a once-daily oral small-molecule FGFR inhibitor. The molecule occupies the kinase ATP-binding site and reduces receptor-mediated phosphorylation.
After the report confirms an FGFR3 mutation and an FGFR3 fusion, a protocol using an intermittent oral FGFR inhibitor gives daily tablets for 14 days followed by 7 days off. Serum phosphate measurements and scheduled eye examinations inform dose interruptions and adjustments.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
For example, a biological sample taken from a patient may be analysed to determine whether a condition or disease, such as cancer, that the patient is or may be suffering from is one which is characterised by a genetic abnormality or abnormal protein expression which leads to up-regulation of the levels or activity of FGFR, VEGFR and/or PDGFR or to sensitisation of a pathway to normal FGFR, VEGFR and/or PDGFR activity, or to upregulation of these growth factor signalling pathA · US 2012/0035171 A1 · ¶ 565
In addition, genetic aberrations of the FGFR3 receptor tyrosine kinase such as chromosomal translocations or point mutations resulting in ectopically expressed or deregulated, constitutively active, FGFR3 receptors have been identified and are linked to a subset of multiple myelomas, bladder and cervical carcinomas (Powers, C.B · US 2012/0041000 A1 · ¶ 445
Identification of an individual carrying a mutation in FGFR, VEGFR and/or PDGFR may mean that the patient would be particularly suitable for treatment with a FGFR, VEGFR and/or PDGFR inhibitor.A · US 2012/0035171 A1 · ¶ 574
Identification of an individual carrying a mutation in FGFR. VEGFR and/or PDGFR may mean that the patient would be particularly suitable for treatment with a FGFR, VEGFR and/or PDGFR inhibitor.B · US 2012/0041000 A1 · ¶ 450
An empty cell means only that no passage was reproduced there.
The invention relates to new bicyclic heterocyclyl derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.A · US 2012/0035171 A1 · ¶ 1
The invention relates to new bicyclic heterocyclyl derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.B · US 2012/0041000 A1 · ¶ 1
patent.fyi, US 2026/0355185 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355185/, SHA-256 423ec6336c28c7eaa8affa531fc699be59ed2a6d16482d0f70541cd47c4b57ab